Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
Citation Manager Formats

Article Information
- Received January 8, 2018
- Accepted in final form March 5, 2018
- First Published April 5, 2018.
Author Information
- Goran Rakocevic, MD, FAAN,
- Ubaldo Martinez-Outschoorn, MD and
- Marinos C. Dalakas, MD, FAAN
- Goran Rakocevic, MD, FAAN,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ubaldo Martinez-Outschoorn, MD and
NONE
NONE
NONE
American Journal of Pathology, Editorial Board, 2012-2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Otsuka Pharmaceuticals
National Institutes of Health-National Cancer Institute of USA, Grant number: CA175193, (2013-2018)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marinos C. Dalakas, MD, FAAN
Serves on the CIDP steering committee for Novartis and on DSMB for Baxalta and Octapharma
NONE
Merck/Serono, OCTAPHARMA, PFIZER AG
1. Neurology, editorial board (5 years, not compensated); 2)BMC Neurology (Section Editor, 5 years not compensated); 3) Acta Myologica, editorial board (5 years, not compensated); 5)Acta Neurologica Scandinavica editorial board ( 5 years, not compensated); 6)Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated)
NONE
NONE
NONE
Therapath, Baxter, Octapharma, CSL, Dysimmune Diseases Foundation
NONE
NONE
NONE
Received Institutional support to Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, CSL, Biogen and Newfactor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
- Correspondence
Dr. Dalakas marinos.dalakas{at}jefferson.edu
Article usage
Cited By...
Letters: Rapid online correspondence
- Author Response: Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathyMarinos C. Dalakas, Ubaldo Martinez-Outschoorn and Goran RakocevicPublished May 04, 2018
- RE: Obinutuzumab, a new anti-CD20 antibody, is active and effective in anti-MAG antibody polyneuropathy.Chiara Briani, Andrea Visentin, Alessandro Salvalaggio, Mario Cacciavillani and Livio TrentinPublished April 16, 2018
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.